Predicting Treatment Side Effects in Older Adults With Head and Neck Cancer
Tests a tool predicting side effects in older adults with head and neck cancer.
Plain-language title generated from the registry record
Registry title: Predicting Toxicity in Elderly Patients With Head and Neck Cancer
Key facts
- Where
- Milan, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 70 and 99 years old?
Source: NCT06344208, who can take part
Where in Italy
- European Institute of OncologyMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- European Institute of Oncology
- Trial code
- NCT06344208
- Record updated
- 24 March 2026
- Original description
Predicting toxicity in elderly patients with head and neck cancer:Read full original descriptionShow less
Predicting Toxicity in Elderly Patients With Head and Neck Cancer: Validating a Disease-oriented Toxicity Predictive Tool and Integrating it With Available Screening Tools for Better Outcomes
Predicting toxicity in elderly patients with head and neck cancer:
validating a disease-oriented toxicity predictive tool and integrating it with avail-able screening tools for better outcomes.
Inclusion: Patients aged ≥ 70 years; Histological diagnosis of squamous cell or undifferentiated HNC in stage III-IV AJCC ed VIII (si-nonasal, nasopharynx, oral cavity, oropharynx, unknown primary with HPV pos, larynx and hy-popharynx) and candidated to curative non surgical treatment (radiotherapy alone, Chemora-diation with platinum salts; radiation+cetuximab); Evaluable disease accordingly to RECIST criteria 1.1; Willing of sign a written informed consent; Adequate organ function.
Exclusion: Patients who received systemic treatments in the past for other primary tumors; Patient with cancer in other sites than HN < than 2 years except for prostate cancer cT1-2, Gleason 3+3, NIMBC, initial Non Melanoma Skin Cancer, in situ cervical cancer); PS ECOG 3-4.